For this review, the authors searched for randomized controlled trials published in MEDLINE, Embase, and Cochrane CENTRAL ...
Tirzepatide, a weekly GLP-1 and GIP drug, produced weight loss of up to 17.8% after 72 weeks. Semaglutide, a weekly GLP-1 ...
The FDA has approved Liraglutide Injection, the first generic version of Victoza, for the treatment of type 2 diabetes.
Danish pharmaceutical giant Novo Nordisk A/S (NYSE:NVO) submitted a Citizen Petition to the FDA requesting the exclusion of ...
In its Citizen Petition to the FDA, Novo Nordisk argued that there is no clinical need to allow compounding for liraglutide.
Novo Nordisk has filed another Citizen's Petition with the FDA seeking to block compounding pharmacies in the US from making ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback